Raymond James & Associates Has $110.58 Million Holdings in Edwards Lifesciences Co. (NYSE:EW)

Raymond James & Associates decreased its stake in Edwards Lifesciences Co. (NYSE:EW) by 8.2% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 1,675,733 shares of the medical research company’s stock after selling 149,497 shares during the period. Raymond James & Associates’ holdings in Edwards Lifesciences were worth $110,582,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. RFG Advisory LLC increased its holdings in shares of Edwards Lifesciences by 7.2% during the first quarter. RFG Advisory LLC now owns 7,784 shares of the medical research company’s stock worth $744,000 after buying an additional 521 shares in the last quarter. Ballentine Partners LLC increased its holdings in Edwards Lifesciences by 23.1% during the 1st quarter. Ballentine Partners LLC now owns 5,236 shares of the medical research company’s stock valued at $500,000 after purchasing an additional 984 shares in the last quarter. CHICAGO TRUST Co NA raised its position in Edwards Lifesciences by 7.7% in the 1st quarter. CHICAGO TRUST Co NA now owns 5,306 shares of the medical research company’s stock valued at $507,000 after purchasing an additional 381 shares during the last quarter. Global Assets Advisory LLC acquired a new position in Edwards Lifesciences in the first quarter worth $3,053,000. Finally, Harbor Investment Advisory LLC grew its holdings in shares of Edwards Lifesciences by 2.9% during the first quarter. Harbor Investment Advisory LLC now owns 14,025 shares of the medical research company’s stock worth $1,340,000 after purchasing an additional 396 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on EW. Baird R W cut Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 25th. Robert W. Baird downgraded shares of Edwards Lifesciences from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $102.00 to $70.00 in a research note on Thursday, July 25th. Royal Bank of Canada decreased their price target on shares of Edwards Lifesciences from $85.00 to $75.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. Wells Fargo & Company dropped their price objective on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a research report on Monday, September 9th. Finally, Evercore ISI decreased their price objective on Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating on the stock in a research report on Tuesday, October 1st. Fifteen equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $75.81.

Insiders Place Their Bets

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 14th. The shares were sold at an average price of $66.08, for a total value of $330,400.00. Following the completion of the transaction, the vice president now owns 46,936 shares in the company, valued at $3,101,530.88. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Edwards Lifesciences news, VP Daveen Chopra sold 1,250 shares of the business’s stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total value of $87,437.50. Following the sale, the vice president now owns 29,333 shares in the company, valued at approximately $2,051,843.35. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 14th. The stock was sold at an average price of $66.08, for a total transaction of $330,400.00. Following the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at $3,101,530.88. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 16,250 shares of company stock worth $1,099,238. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of EW stock opened at $70.27 on Monday. The firm has a market capitalization of $42.34 billion, a price-to-earnings ratio of 30.29, a price-to-earnings-growth ratio of 2.83 and a beta of 1.13. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $96.12. The company has a quick ratio of 2.87, a current ratio of 3.71 and a debt-to-equity ratio of 0.08. The firm has a fifty day moving average of $67.81 and a 200-day moving average of $79.08.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Wednesday, July 24th. The medical research company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.69 by $0.01. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The company had revenue of $1.63 billion during the quarter, compared to the consensus estimate of $1.65 billion. During the same period in the prior year, the company earned $0.66 earnings per share. The company’s revenue for the quarter was up 6.7% compared to the same quarter last year. On average, equities research analysts forecast that Edwards Lifesciences Co. will post 2.71 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.